Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria.
Cell Chem. Bio. 29, 1434-1445.e7 (2022)
Bacteriophages are potent therapeutics against biohazardous bacteria, which rapidly develop multidrug resistance. However, routine administration of phage therapy is hampered by a lack of rapid production, safe bioengineering, and detailed characterization of phages. Thus, we demonstrate a comprehensive cell-free platform for personalized production, transient engineering, and proteomic characterization of a broad spectrum of phages. Using mass spectrometry, we validated hypothetical and non-structural proteins and could also monitor the protein expression during phage assembly. Notably, a few microliters of a one-pot reaction produced effective doses of phages against enteroaggregative Escherichia coli (EAEC), Yersinia pestis, and Klebsiella pneumoniae. By co-expressing suitable host factors, we could extend the range of cell-free production to phages targeting gram-positive bacteria. We further introduce a non-genomic phage engineering method, which adds functionalities for only one replication cycle. In summary, we expect this cell-free methodology to foster reverse and forward phage engineering and customized production of clinical-grade bacteriophages.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Biosafety ; Cell-free Production ; Multidrug-resistant Bacteria ; Non-genomic Phage Engineering ; Non-structural Phage Proteins ; Personalized Medicine ; Phage Therapy ; Therapeutic Bacteriophages ; Time-resolved Proteomics
ISSN (print) / ISBN
2451-9448
e-ISSN
2451-9456
Zeitschrift
Cell Chemical Biology
Quellenangaben
Band: 29,
Heft: 9,
Seiten: 1434-1445.e7
Verlag
Cell Press
Verlagsort
Cambridge, Massachusetts
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Insitute of Synthetic Biomedicine (ISBM)
Förderungen
Technische Universität München
Institut Pasteur
Deutsche Forschungsgemeinschaft
Shanmuga Sozhamannan
Laboratory for Molecular and Cellular Technology
JPEO
Federal Ministry of Economy and Climate Action
Defense Biological Product Assurance Office
CBRND-EB
Bavarian Ministry for Science
Institut Pasteur
Deutsche Forschungsgemeinschaft
Shanmuga Sozhamannan
Laboratory for Molecular and Cellular Technology
JPEO
Federal Ministry of Economy and Climate Action
Defense Biological Product Assurance Office
CBRND-EB
Bavarian Ministry for Science